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Abstract: Asthma–COPD overlap syndrome (ACOS) is a commonly encountered chronic 
airway disease. However, ACOS is still a consensus-based clinical phenotype and the under-
lying inflammatory mechanisms are inadequately characterized. To clarify the inflammatory 
mediatypical for ACOS, five biomarkers, namely interleukin (IL)-13, myeloperoxidase (MPO), 
neutrophil gelatinase-associated lipocalin (NGAL), chitinase-like protein (YKL-40), and IL-6, 
were selected. This study hypothesized that sputum biomarkers relevant for airway inflammation 
in asthma (IL-13), COPD (MPO, NGAL), or in both asthma and COPD (YKL-40, IL-6) could 
be used to differentiate ACOS from COPD and asthma. The aim of this study was to charac-
terize the inflammatory profile and improve the recognition of ACOS. Induced sputum levels 
of IL-13, MPO, NGAL, YKL-40, and IL-6 were measured by enzyme-linked immunosorbent 
assay/Luminex assay in a Finnish discovery cohort (n=90) of nonsmokers, smokers, and patients 
with asthma, COPD, and ACOS and validated in a Japanese cohort (n=135). The classification 
accuracy of potential biomarkers was compared with area under the receiver operating charac-
teristic curves. Only sputum NGAL levels could differentiate ACOS from asthma (P,0.001 
and P,0.001) and COPD (P,0.05 and P=0.002) in the discovery and replication cohorts, 
respectively. Sputum NGAL levels were independently correlated with the percentage of pre-
bronchodilator forced expiratory volume in 1 second predicted in multivariate analysis in the 
discovery and replication cohorts (P=0.001 and P=0.002, respectively). In conclusion, sputum 
biomarkers reflecting both airway inflammation and remodeling of the tissue show potential in 
differentiation between asthma, COPD, and ACOS.
Keywords: COPD pathology, asthma, ACOS
Introduction
The asthma–COPD overlap syndrome (ACOS) has recently been recognized as a 
consensus-based clinical phenotype sharing the features of asthma and COPD.1–3 
Approximately 20%–50% of patients with irreversible airway obstruction show 
airflow variability characteristic to asthma.4–7 Differential diagnosis of ACOS from 
asthma and COPD is increasingly important, since ACOS has a poor prognosis and 
different treatment guidelines. ACOS is associated with low health-related quality 
of life,6 increased exacerbation rate and hospital admissions, a rapid decline in lung 
function, and high mortality.5,6,8 However, ACOS cannot be diagnosed unambiguously 
on the basis of lung function tests, patients’ demographics, and sputum cell counts 
or by imaging of the lungs.6,9,10 There is an unmet need to develop novel diagnostic 
biomarkers for clinical assessment of ACOS.
Although the inflammatory pathways of asthma and COPD are markedly 
different,11,12 they coincide in ACOS, and both eosinophils and neutrophils in sputum 
are characteristic for ACOS. Clinically, the main interest would be to identify those 
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patients with ACOS who could be responsive to inhaled 
corticosteroids.13 For this, the assessment of fractional exhaled 
nitric oxide or immunoglobulin E in COPD patients could be 
useful.14 For the current study, interleukin (IL)-13,15,16 which 
is a T-helper 2 type marker known to be important in eosino-
philic inflammation and asthma, was analyzed. In addition, 
chitinase-like protein (YKL-40),17,18 which is elevated in both 
asthma and COPD, was selected.19 IL-6 was selected because 
its serum and sputum levels are associated with impaired 
lung function,15,20,21 and elevated serum IL-6 levels were 
detected in patients with ACOS.22 In addition, myeloperoxi-
dase (MPO) and neutrophil gelatinase-associated lipocalin 
(NGAL) were assessed based on the authors’ earlier findings 
that suggested enhanced neutrophil-mediated inflammation 
and/or airway epithelial injury in ACOS.9
This study hypothesized that sputum biomarkers relevant 
for airway inflammation in asthma (IL-13), COPD (MPO, 
NGAL), or in both asthma and COPD (YKL-40, IL-6) 
could be used to differentiate ACOS from COPD and asthma 
and further could be used to improve the determination and 
recognition of ACOS.
Subjects and methods
subjects
The discovery cohort consisted of 90 volunteer individuals 
who were a part of the cohort previously reported in Iwamoto 
et al.9 The cohort size was smaller than the original one 
because of the consumption of sputum samples. The patients, 
who were a part of the longitudinally followed cohort of 
Finnish asthma and COPD patients (FinnCADStudy),6,9,23 
were recruited from the Helsinki University Hospital. Based 
on their medical history and self-reported questionnaire 
data, the subjects were categorized into five groups: healthy 
nonsmokers (NSs, n=14), healthy smokers (HSs, n=14), 
and patients with asthma (n=24), COPD (n=20), and ACOS 
(n=18). Spirometry with a bronchodilator test and the diffus-
ing capacity of the lung for carbon monoxide were performed 
on all participants. The control subjects (NSs and HSs) 
consisted of responders to an advertisement in the Helsinki 
University Hospital and the local media. These participants 
were asymptomatic, never, or current smokers with no history 
of lung disease confirmed by a normal lung function with 
post-bronchodilator forced expiratory volume in 1 second 
(FEV
1
)/forced vital capacity (FVC) $0.7 in spirometry.
The diagnosis of asthma was based on the British 
Guidelines on Asthma Management24 and defined as revers-
ible airflow obstruction with a post-bronchodilator FEV
1
/
FVC $0.7, with one or more of the following findings: a 
post-bronchodilator increase in FEV
1
 of $12%, a broncho-
dilator response of $15% or diurnal variation of $20% in 
peak expiratory flow recording, moderate-to-severe bronchial 
hyperreactivity, or a decrease in FEV
1
 of $15% in the exer-
cise test. COPD was diagnosed according to the American 
Thoracic Society/European Respiratory Society Task Force 
recommendations23,25,26 and defined by incompletely reversible 
airflow obstruction with a post-bronchodilator FEV
1
/
FVC ,0.7.1 ACOS was identified by the features that it shares 
with both asthma and COPD according to the Global Initiative 
for Asthma guidelines2 and Global Initiative for Obstructive 
Lung Diseases strategy.1 In the ACOS group, the age of 
onset was .40 years and all the patients had history of 
smoking. The patients with ACOS had increased airflow 
variability and incompletely reversible airflow obstruction. 
Patients with COPD and ACOS had no history of alpha-1- 
antitrypsin deficiency in their family. All patients had 
respiratory symptoms and were current or former smokers 
(.10 pack-years) when developed their lung disease. None 
of the patients received oral glucocorticoid treatment or 
experienced an exacerbation during the study period. Signs 
of atopy were not included in the diagnostic criteria.
The Japanese replication cohort (n=135) consisted of 
NSs (n=22), HSs (n=40), and patients with asthma (n=21), 
COPD (n=35), and ACOS (n=17). The diagnosis of asthma 
was assessed by specialists in respiratory medicine using the 
Global Initiative for Asthma guidelines.2 COPD diagnosis 
was based on long-term smoking (.10 pack-years) and a pre-
bronchodilator FEV
1
/FVC ,0.7.1,27,28 The individuals in the 
ACOS group consisted of patients who had been diagnosed 
with both asthma and COPD. All the patients with asthma, 
COPD, and ACOS were in stable condition and were using 
regular inhaled medications. For healthy control subjects, 
only prebronchodilator spirometries were performed, and 
their prebronchodilator FEV
1
/FVC values were .0.7.
This study was approved by the Ethics Committees 
of Helsinki University Central Hospital and Hiroshima 
University and conducted in accordance with the ethical 
standards established in the 1975 Declaration of Helsinki. 
All participants provided written informed consent.
sampling of sputum
Sputum was induced by inhalation of hypertonic saline and 
treated with dithioerythritol (Sigma-Aldrich Co., St Louis, 
MO, USA) as recommended by the European Respiratory 
Society Task Force and described earlier in detail.9,29,30 The 
supernatant was frozen at −80°C for biochemical analyses. 
Cell viability was studied with Trypan blue in a Burker 
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chamber.31 Cytocentrifuge preparations were made by 
Cytospin (Shandon Cytospin 3) and centrifuged at 450 rpm 
for 6 minutes. The slides were stained with May–Grunwald–
Giemsa solution (EMD Millipore, Billerica, MA, USA) for 
cell differential counts. Detailed cell profiles were assessed 
based on 400 cells counted from each slide. Only the repre-
sentative samples with ,70% of squamous epithelial cells 
were accepted for the assessments.9,31 The slides were frozen 
at −20°C. Induction of the sputum samples in the Japanese 
cohort has been described earlier.32
enzyme-linked immunosorbent assay 
and luminex assays
YKL-40 was measured by Quantikine ELISA (R&D 
Systems, Inc., Minneapolis, MN, USA), IL-6 by Magnetic 
Human High Sensitivity Luminex assay (R&D Systems, 
Inc.), IL-13 by enzyme-linked immunosorbent assay (ELISA; 
USCN Life Science Inc., Wuhan, People’s Republic of 
China), MPO by ELISA (Abnova Inc., Walnut, CA, USA), 
and NGAL by ELISA (USCN Life Science Inc.) according 
to the manufacturers’ instructions. The minimal detectable 
dose for YKL-40, IL-6, IL-13, MPO, and NGAL were 
3.55 pg/mL, 0.14 pg/mL, 5.7 pg/mL, 0.78 ng/mL, and 
17 pg/mL, respectively. The analysis of MPO and NGAL in 
the discovery cohort has been performed earlier but added in 
the present analysis to identify the most informative panel 
of biomarkers.9
statistical analysis
The demographics are expressed as mean ± standard devia-
tion, and the biomarker concentrations as medians with 
interquartile range. All statistical analyses were performed 
with the SPSS 20.0 software program (IBM Corporation, 
Armonk, NY, USA). Comparisons between groups were 
evaluated by the Kruskal–Wallis test followed by the Mann–
Whitney U test, when appropriate. Sputum biomarkers were 
further analyzed by the area under the curve (AUC) statistics 
for their predictive capability to distinguish ACOS from 
asthma, and ACOS and asthma from COPD or NSs. Spear-
man’s correlations of the induced sputum marker levels with 
age, lung function, and sputum cell counts were calculated. 
Multivariate stepwise regression analysis was performed to 
obtain the variables to model ACOS. Due to the differences 
in sputum processing, such as a single versus three times 
inhalation of hypertonic saline in the discovery and repli-
cation cohort, respectively, the concentrations of sputum 
biomarkers were not directly comparable between the two 
cohorts. To make the comparison feasible, raw data was 
used in the comparisons within each cohort and standardized 
data (Z-scores) in the comparisons between the two cohorts. 
P-values of ,0.05 were considered statistically significant.
Results
subject characteristics
The characteristics of the study subjects in the discovery 
cohort are shown in Table 1. Healthy controls were ∼10 years 
younger than the patients. Patients with COPD and ACOS 
had more pack-years and significantly lower FEV
1
, 
FEV
1
/FVC ratio, and diffusing capacity of the lung for car-
bon monoxide compared with those in the NS and asthma 
groups (Table 1). The patients with ACOS had significant 
reversibility in the bronchodilation test and diurnal variation 
of peak expiratory flow compared with those among the 
COPD patients. None of the participants had experienced an 
exacerbation or a respiratory tract infection within a month 
prior the study.
Successfully induced sputum samples were obtained 
from 90 individuals. The representativeness of samples 
was confirmed by cytospin centrifugation cell profiles. As 
expected, patients in the asthma (n=24) and ACOS (n=18) 
groups had a higher percentage of sputum eosinophil com-
pared with that in the HS group (n=14). In addition, COPD 
(n=20) and ACOS groups had a higher percentage of sputum 
neutrophils compared with that in the NS (n=14) and HS 
groups (Table 1).
The characteristics of the study subjects in the replication 
cohort are shown in Table 2. There were no differences in 
pre-FEV
1
/FVC, pack-years, neutrophil%, and eosinophil% 
between the patients with ACOS in the replication and in 
the discovery cohorts. However, patients with ACOS had 
greater pre-FEV
1
% and pre-FVC% values in the replication 
cohort than in the discovery cohort (P=0.001 and P,0.001, 
respectively).
sputum MPO and Il-13 were elevated 
in aCOs when compared with healthy 
controls
The sputum levels of MPO and IL-13 were significantly 
increased in the ACOS groups when compared with the 
levels in the NS (P=0.012 and P,0.001, respectively) and 
HS groups (P=0.008 and P,0.001, respectively; Table 1). 
There was also a significant difference in sputum MPO 
levels between the ACOS and asthma groups (P=0.004). 
However, the sputum MPO and IL-13 levels could not 
distinguish ACOS from COPD (P=0.128 and P=0.088, 
respectively).
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sputum YKl-40, Il-6, and ngal were 
elevated in aCOs when compared with 
COPD and asthma
The sputum levels of YKL-40, IL-6, and NGAL were 
significantly increased in ACOS when compared with the 
NS (P,0.001, P,0.001, P,0.001, respectively) and HS 
groups (P,0.001, P=0.001, and P=0.001, respectively; 
Table 1). In addition, the sputum levels of YKL-40, IL-6, 
and NGAL were significantly increased in ACOS when com-
pared with the asthma (P=0.001, P,0.001, and P,0.001, 
respectively) and COPD groups (P=0.002, P=0.006, and 
P=0.026, respectively). Sputum IL-6 and NGAL were also 
significantly increased in the COPD group when compared 
with the asthma group (P=0.034 and P=0.025, respectively), 
while sputum YKL-40 levels were not significantly different 
between the COPD and asthma groups (P.0.05).
sputum YKl-40, Il-6, and ngal 
could differentiate aCOs from COPD 
and asthma
A receiver operating characteristic curve analysis was car-
ried out to evaluate the sensitivity, specificity, and diagnostic 
accuracy of the classical variables and the novel biomarkers 
(Table 3). All tested sputum biomarkers (MPO, NGAL, 
Table 1 Clinical characteristics and biomarker concentrations of the study subjects across the discovery cohort (n=90)
Discovery cohort Nonsmokers 
(n=14)
Healthy 
smokers (n=14)
Asthma  
(n=24)
COPD  
(n=20)
ACOS  
(n=18)
P-value
Demographics
Female/male 5/9 5/9 15/9 8/12 6/12
age (years) 46.2 (15.4) 48.4 (10.9) 58.3 (8.3) 59.3 (7.0) 61.8 (6.5) ,0.001
BMI (kg/m2) 28.2 (4.6) 26.6 (4.8) 26.0 (4.5) 24.6 (4.0) 28.2 (6.5) 0.263
allergy, n (%) 1 (7) 7 (50) 11 (46) 9 (45) 6 (33)
ICs use, n (%) – – 20 (83) 9 (45) 13 (72)
smoking status
Former/current – 0/14 9/6 7/12 11/7
Pack-years – 27.1 (16.1) 13.0 (16.0) 37.2 (17.3) 42.5 (17.7) ,0.001
Prebronchodilator
FVC (l) 4.8 (1.1) 4.7 (1.4) 3.1 (0.7) 3.3 (1.0) 3.0 (1.1) ,0.001
FVC% predicted 103.6 (9.4) 98.6 (15.1) 81.1 (17.7) 81.7 (16.5) 69.3 (18.6) ,0.001
FeV1 (l) 4.0 (1.0) 3.8 (1.1) 2.3 (0.6) 1.9 (0.8) 1.5 (0.6) ,0.001
FeV1% predicted 104.1 (11.0) 96.5 (15.3) 74.0 (15.6) 56.9 (18.7) 44.8 (14.8) ,0.001
FeV1/FVC% 82.1 (3.7) 79.4 (5.2) 74.2 (5.0) 56.4 (13.6) 53.6 (10.7) ,0.001
Post-bronchodilator
FVC (l) 4.8 (1.1) 4.7 (1.4) 3.2 (0.7) 3.4 (0.9) 3.3 (1.0) ,0.001
FVC% predicted 102.6 (8.9) 98.8 (15.9) 83.1 (14.7) 83.4 (16.7) 75.5 (16.9) ,0.001
FeV1 (l) 4.0 (1.0) 3.8 (1.1) 2.5 (0.6) 1.9 (0.8) 1.8 (0.6) ,0.001
FeV1% predicted 105.9 (10.6) 98.5 (15.5) 78.8 (14.0) 58.3 (19.1) 51.6 (13.7) ,0.001
FeV1/FVC% 84.4 (3.7) 80.9 (5.0) 76.8 (4.4) 55.6 (12.4) 55.7 (10.8) ,0.001
DlCO% predicted 99.0 (9.0) 89.8 (10.2) 82.2 (17.8) 53.2 (20.2) 67.9 (18.7) ,0.001
reversibility test
ΔFeV1a (ml) 72.9 (175.9) 79.3 (203.2) 146.3 (166.8) 53.5 (80.6) 231.1 (187.4) 0.004
ΔFeV1%a 1.9 (4.6) 2.2 (6.0) 6.5 (7.4) 2.8 (4.4) 17.6 (15.6) ,0.001
PeF diurnal variability (%) 25.6 (12.1) 13.5 (5.8) 27.5 (13.6) 0.003
Differential sputum cell counts (%)
eosinophils 1.9 (3.8) 0.3 (0.6) 5.1 (9.2) 2.4 (4.9) 6.8 (9.8) 0.001
neutrophils 36.8 (8.0) 42.5 (20.8) 53.6 (23.4) 62.8 (20.3) 64.8 (15.5) ,0.001
sputum biomarker concentrations
Il-6 (pg/ml) 18.6 (8.1, 49.5) 102.0 (78.0, 137.2) 77.5 (30.8, 121.2) 286.3 (61.6, 412.0) 605.7 (291.8, 808.7) ,0.001
YKl-40 (ng/ml) 22.5 (8.9, 44.0) 15.0 (8.7, 35.0) 47.8 (22.1, 100.5) 50.4 (37.7, 64.4) 142.4 (97.5, 521.2) ,0.001
Il-13 (pg/ml) 53.9 (27.6, 82.4) 40.7 (29.4, 50.1) 159.0 (57.7, 332.4) 141.6 (86.6, 255.7) 256.5 (133.6, 499.1) ,0.001
ngal (µg/ml) 1.2 (0.9, 3.7) 2.0 (1.1, 3.5) 2.3 (1.4, 3.6) 3.9 (2.4, 5.7) 5.2 (4.1, 14.2) ,0.001
MPO (µg/ml) 2.9 (2.1, 16.8) 4.3 (1.5, 14.0) 6.3 (3.8, 11.7) 12.1 (5.8, 22.7) 21.7 (10.9, 29.6) 0.005
Notes: The demographics are presented as mean (sD) unless otherwise stated. The biomarker concentrations are presented as medians (IQr). P-value for the differences 
was analyzed by Kruskal–Wallis H test. Δ, change in. aImprovement in FeV1 after 400 µg of salbutamol.
Abbreviations: aCOs, asthma–COPD overlap syndrome; BMI, body mass index; DlCO, diffusing capacity of the lung for carbon monoxide; FeV1, forced expiratory volume 
in 1 second; FVC, forced vital capacity; ICs, inhaled corticosteroids; Il, interleukin; IQr, interquartile range; MPO, myeloperoxidase; ngal, neutrophil gelatinase-associated 
lipocalin; PEF, peak expiratory flow; SD, standard deviation; YKL-40, chitinase-3-like protein 1.
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YKL-40, IL-6, and IL-13) could distinguish ACOS sig-
nificantly from the other non-ACOS groups (AUC .0.7). 
Importantly, sputum biomarkers YKL-40, IL-6, and NGAL 
could distinguish ACOS significantly from both asthma and 
COPD (AUC .0.7). In addition, sputum MPO levels could 
differentiate ACOS from asthma, but not ACOS from COPD. 
Sputum IL-13 levels did not significantly separate ACOS 
from asthma or ACOS from COPD.
relationships between the sputum 
biomarkers and clinical characteristics
The study subjects in the asthma, COPD, and ACOS groups 
were pooled to analyze the correlations between biomarker 
concentrations as the dependent factor and clinical variables. 
Multivariate analysis revealed pack-years and age to be 
the independent predictors for sputum MPO, whereas age 
and pre-FEV
1
% were independent predictors for YKL-40 
Table 2 Clinical characteristics and biomarker concentrations of the study subjects across the replication cohort (n=135)
Replication 
cohort
Nonsmokers 
(n=22)
Healthy smokers 
(n=40)
Asthma (n=21) COPD (n=35) ACOS (n=17) P-value
Demographics
Females/males 13/9 5/35 17/4 1/34 3/14
age (years) 58.2 (10.8) 63.4 (11.2) 42.0 (15.4) 72.2 (8.1) 65.9 (8.9) ,0.001
BMI (kg/m2) 23.8 (3.5) 24.0 (3.2) 24.6 (5.4) 23.5 (3.0) 24.2 (3.2) 0.952
ICs use, n (%) – – 16 (76) – 15 (88)
Pack-years – 37.1 (23.7) 4.3 (12.5) 47.6 (21.9) 40.7 (16.6) ,0.001
Prebronchodilator
FVC (l) 2.9 (0.7) 3.6 (1.0) 3.1 (1.0) 3.1 (0.8) 3.2 (0.6) 0.079
FVC% predicted 95.6 (17.3) 100.0 (16.6) 100.4 (17.5) 93.2 (17.4) 94.9 (13.2) 0.302
FeV1 (l) 2.4 (0.6) 2.8 (0.8) 2.5 (0.7) 1.9 (0.5) 1.8 (0.5) ,0.001
FeV1% predicted 96.0 (16.7) 94.1 (17.7) 94.6 (16.2) 69.6 (16.5) 64.3 (15.3) ,0.001
FeV1/FVC% 83.2 (7.1) 77.1 (5.7) 80.7 (6.1) 59.8 (8.6) 55.2 (11.5) ,0.001
Differential sputum cell counts (%)
eosinophils 2.6 (4.1) 2.0 (3.2) 12.0 (17.4) 3.2 (8.7) 9.2 (17.1) 0.051
neutrophils 64.2 (27.7) 70.0 (20.9) 46.2 (26.0) 72.4 (17.4) 66.1 (24.8) 0.008
sputum biomarker concentrations
Il-6 (pg/ml) 4.4 (1.5, 11.4) 8.3 (4.0, 18.2) 11.2 (4.0, 20.1) 11.6 (3.4, 28.1) 21.8 (7.4, 54.2) 0.017
YKl-40 (ng/ml) 10.1 (4.5, 27.7) 18.3 (5.0, 29.4) 17.4 (8.2, 21.7) 21.3 (11.4, 31.1) 20.6 (13.4, 30.6) 0.138
Il-13 (pg/ml) 28.7 (18.6, 43.5) 39.9 (25.7, 70.4) 14.7 (7.4, 47.4) 39.6 (33.1, 52.0) 39.1 (22.4, 59.2) 0.032
ngal (ng/ml) 53.9 (23.7, 91.8) 82.4 (45.8, 167.0) 50.1 (33.4, 163.5) 106.2 (60.8, 178.6) 209.3 (160.0, 304.9) ,0.001
MPO (ng/ml) 165.2 (101.4, 300.0) 170.3 (111.3, 329.0) 139.4 (98.3, 254.6) 251.4 (166.0, 365.5) 152.1 (118.7, 307.4) 0.330
Notes: The demographics are presented as mean (sD) unless otherwise stated. The biomarker concentrations are presented as medians (IQr). P-value for the differences 
was analyzed by Kruskal–Wallis H test. Comparisons between groups were evaluated by the Kruskal–Wallis test followed by the Mann–Whitney U test.
Abbreviations: aCOs, asthma–COPD overlap syndrome; BMI, body mass index; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICs, inhaled 
corticosteroids; Il, interleukin; IQr, interquartile range; MPO, myeloperoxidase; ngal, neutrophil gelatinase-associated lipocalin; sD, standard deviation; YKl-40, chitinase-
3-like protein 1.
Table 3 rOC analysis for sputum biomarkers in the discovery cohort
Discovery cohort IL-6 (pg/mL) YKL-40 (ng/mL) IL-13 (pg/mL) NGAL (µg/mL) MPO (µg/mL)
aCOs versus non-aCOs
aUC (95% CI) 0.887 (0.813–0.962) 0.854 (0.749–0.959) 0.753 (0.636–0.870) 0.814 (0.697–0.932) 0.737 (0.590–0.883)
Optimal threshold .200.5 .90.4 .99.7 .4.0 .14.5
Sensitivity/specificity 0.938/0.757 0.833/0.845 0.882/0.515 0.833/0.750 0.706/0.789
P-value ,0.001 ,0.001 0.001 ,0.001 0.003
aCOs versus COPD
aUC (95% CI) 0.772 (0.617–0.926) 0.794 (0.638–0.951) 0.665 (0.486–0.844) 0.711 (0.541–0.881) 0.647 (0.460–0.834)
Optimal threshold .479.8 .78.9 .175.2 .4.0 .14.3
Sensitivity/specificity 0.625/0.850 0.833/0.800 0.647/0.700 0.833/0.600 0.706/0.650
P-value 0.006 0.002 0.088 0.026 0.128
aCOs versus asthma
aUC (95% CI) 0.930 (0.853–1.000) 0.814 (0.681–0.947) 0.638 (0.463–0.812) 0.833 (0.704–0.963) 0.767 (0.598–0.937)
Optimal threshold .199.5 .90.4 .377.8 .3.8 .14.2
Sensitivity/specificity 0.938/0.875 0.833/0.750 0.412/0.864 0.833/0.792 0.706/0.917
P-value ,0.001 0.001 0.145 ,0.001 0.004
Abbreviations: ACOS, asthma–COPD overlap syndrome; AUC, area under the curve; CI, confidence interval; IL, interleukin; MPO, myeloperoxidase; NGAL, neutrophil 
gelatinase-associated lipocalin; rOC, receiver operating characteristic; YKl-40, chitinase-3-like protein 1.
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(Table 4). Sputum IL-6 was an independent predictor for 
pre-FEV
1
% predicted and pack-years, and sputum NGAL 
was independently associated with pre-FEV
1
% predicted 
(Table 4 and Figure 1A and B).
Validation of the findings in an 
independent replication data set
The clinical data and the levels of sputum biomarkers 
(MPO, NGAL, YKL-40, IL-6, and IL-13) in the replication 
cohort are shown in Table 2. Sputum neutrophil% count 
was significantly different between the groups (P=0.008), 
and eosinophil% count showed a tendency of differences 
between the groups (P=0.051).
In the replication cohort, sputum IL-6, NGAL, and IL-13 
levels had statistically significant differences between the 
study groups (Table 2). The sputum levels of IL-6 and NGAL 
were significantly increased in ACOS when compared with the 
NS (P=0.001 and P,0.001, respectively) and the HS groups 
(P=0.018 and P,0.001, respectively) (Table 2). Importantly, 
only sputum NGAL levels were elevated in ACOS when 
compared with the COPD (P=0.002) and asthma (P,0.001) 
groups (Figure 2) and had an increasing trend in COPD when 
compared with those in the asthma group (P=0.068). Other 
sputum biomarkers did not differ significantly between ACOS 
and asthma or between ACOS and COPD in the replication 
cohort, but there was a significant difference in sputum IL-13 
levels between asthma and COPD (P=0.025).
NGAL levels could differentiate ACOS from the other 
study participants (non-ACOS) with an AUC value of 0.827 
(95% CI: 0.727–0.926, P,0.001) in the replication cohort. In 
addition, sputum NGAL could differentiate ACOS from the 
COPD and asthma groups with AUC values of 0.794 (95% 
CI: 0.629–0.924, P=0.002) and 0.840 (95% CI: 0.717–0.964, 
P,0.001), respectively.
The asthma, COPD, and ACOS groups in the replication 
cohort were pooled to analyze the correlations in the univariate 
Table 4 Multivariate stepwise analysis of all subjects with sputum 
biomarker as the dependent variable in patients with asthma, COPD, 
and aCOsa
Discovery cohort β t P-value
sputum Il-6
Pre-FeV1% predicted −0.309 −2.381 0.021
Pack-years 0.262 2.018 0.049
sputum ngal
Pre-FeV1% predicted −0.420 3.498 0.001
sputum YKl-40
age (years) 0.283 2.257 0.028
Pre-FeV1% predicted −0.273 2.183 0.033
sputum MPO
Pack-years 0.390 3.304 0.002
age (years) 0.282 2.388 0.020
Notes: aMultivariate analysis was adjusted for age, body mass index, pack-years, and 
all the significant variables in the univariate analysis.
Abbreviations: aCOs, asthma–COPD overlap syndrome; FeV1, forced expiratory 
volume in 1 second; Il, interleukin; MPO, myeloperoxidase; ngal, neutrophil 
gelatinase-associated lipocalin; YKl-40, chitinase-3-like protein 1.
?????? ???? ????
????????????????
???
???
???
???
???
???
?
?? ?? ?? ?? ??? ??????????????????????
???
???
???
???
???
???
?
??
??????????????????
??
??
?
?? ?? ?? ?? ??? ??????????????????????
???
???
???
???
????
???
?
? ?
Figure 1 Correlation of sputum ngal with pre-FeV1% predicted in patients with asthma, COPD, and aCOs in the discovery (A) and in the replication cohorts (B).
Abbreviations: aCOs, asthma–COPD overlap syndrome; FeV1, forced expiratory volume in 1 second; ngal, neutrophil gelatinase-associated lipocalin.
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and multivariate analyses. Sputum YKL-40 and sputum IL-6 
did not correlate with any clinical parameters. Multivariate 
analysis revealed that sputum IL-13 correlated with pack-
years and sputum MPO correlated with neutrophil% count. 
In agreement with the results from the discovery cohort, 
NGAL levels independently correlated with pre-FEV
1
% 
predicted in the replication cohort (P=0.002, Figure 1B).
Discussion
This study analyzed the biomarkers related to asthma or 
COPD or implicated in both diseases to discover inflamma-
tory profiles typical for ACOS in two independent cohorts. 
The levels of sputum IL-13 and MPO were higher in the 
ACOS patients than in the healthy controls in the discovery 
cohort, but this was not apparent in the replication cohort. In 
both cohorts, the sputum levels of NGAL, IL-6, and YKL-40 
were elevated in ACOS when compared with those of NSs. 
However, only sputum NGAL could differentiate ACOS 
from COPD and asthma in both cohorts.
The most recent treatment guidelines present features that 
characterize ACOS rather than provide a formal definition 
of ACOS.33 Four distinct pathways have been proposed for 
ACOS.34 Airflow limitation in early life can persist through 
adolescence into adulthood and ACOS is more likely than 
severe asthma if other risk factors, such as smoking, are 
present. A second pathway is represented in COPD patients 
with substantial smoking histories or other exposures and 
late-onset features of asthma. A third asthma-dominant 
pathway is represented by asymptomatic adults with air-
way hyperresponsiveness who progress to chronic airflow 
limitation compatible with a diagnosis of COPD. Finally, a 
fourth pathway recognizes the link between early-life risk 
factors and small lungs, with an increased risk of develop-
ment of fixed airflow limitation and asthma. Thus, from the 
molecular genetic point of view, ACOS can represent a very 
heterogeneous group of patients. All patients with ACOS in 
the discovery cohort were either current or former smokers. 
There were eleven patients who mostly represent the second 
COPD-dominant pathway in the discovery cohort, and seven 
patients who developed fixed airway limitation after asthma 
diagnosis. There was more variation in the biomarker levels 
in the replication cohort than in the discovery cohort suggest-
ing that there may be more etiological variability between 
the patients. The final goal would be to identify a panel of 
markers with the optimal capability to dissect the endotypes 
valid for prognosis and in treatment choices.
Elevated IL-6 and YKL-40 levels were observed in 
patients with ACOS in both cohorts although the differences 
between patients with ACOS, asthma, and COPD were not 
statistically significant in the replication cohort. This could 
be explained by the higher etiological variability between the 
patients or by the milder airway limitation. In a recent study, 
elevated serum IL-6 levels were detected in patients with 
ACOS, although systemic IL-6 levels did not differentiate 
COPD from ACOS.22 Circulating biomarkers may also not 
be specific for airway disease unlike sputum samples and 
there is no direct link between systemic and airway inflam-
matory mediators.35
The important finding of this study was that sputum NGAL 
levels were significantly increased in patients with ACOS in 
comparison with the levels in the asthma and COPD groups 
in two independent cohorts. Therefore, although ACOS 
might be a complex and heterogeneous disease, the results 
of the current study further support that increased sputum 
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Figure 2 expression levels of sputum biomarkers in patients with asthma, COPD, and aCOs in the discovery (A) and replication cohorts (B).
Notes: The results represent standardized data (Z-scores), and the solid lines show the median value.
Abbreviations: aCOs, asthma–COPD overlap syndrome; Il, interleukin; MPO, myeloperoxidase; ngal, neutrophil gelatinase-associated lipocalin; YKl-40, chitinase-3-like 
protein 1.
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NGAL might be a characteristic feature of ACOS. Although 
MPO and NGAL are both COPD-related biomarkers, MPO 
is associated with a local activation of neutrophils,9,36,37 
whereas NGAL is not only attributed to activated neutrophils 
but could also be secreted by the respiratory epithelial cells 
in response to inflammatory stimuli9,38 and by myeloid and 
epithelial cells in response to toll-like receptor activation 
during bacterial infections.39,40 Patients with ACOS seem to 
have more frequent exacerbations,41,42 and microorganisms 
are one of the main etiologic factor involved in exacerba-
tions of COPD. Therefore, the sputum NGAL levels might 
be related to airway inflammation and low-grade microbial 
colonization, which predispose patients with ACOS to acute 
viral infections and exacerbations.
In addition, earlier reports have shown that NGAL expres-
sion in lung can be induced by reactive oxygen species.43,44 
Because the pathophysiology of both asthma and COPD is 
associated with oxidative processes induced by environmen-
tal exposures and airway inflammation,45 ACOS might have 
augmented oxidative stress that could result in airway reactiv-
ity, injury, and remodeling and might also relate to increased 
sputum NGAL levels. Finally, it is important that increased 
sputum NGAL was independently correlated with degree of 
airflow limitation in both the discovery and replication cohorts. 
This finding indicates that sputum NGAL may be a candidate 
marker for airway remodeling, but the clinical utility of this 
finding should be tested in a future prospective study.
Although many biomarkers examined in this study are 
likely to be associated with other morbidities, the use of 
sputum may improve their specificity for airway disease. The 
changes in sputum biomarker levels are likely to reflect the 
changes of cell composition and lung function during the 
development of chronic airway disease. Therefore, this study 
results suggest that ACOS could be characterized by media-
tors related to airway inflammation and airway remodeling. 
Future studies with high-throughput design are required to 
fully reveal the transcriptomic or proteomic differences in 
chronic airway disease.
The strength of this study design was that the control 
subjects did not have any other exposures, and the diagno-
sis criteria for asthma, COPD, and ACOS were based on 
international guidelines, sputum cell counts, and clinical 
characteristics of the disease. The sample size was limited, 
but the obtained results were replicated in another indepen-
dent cohort.
Conclusion
The results from the current study indicate that ACOS is 
associated with sputum biomarkers that drive both airway 
inflammation and tissue remodeling, and these biomarkers 
could have diagnostic value in differentiation of ACOS from 
asthma and COPD.
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